The decision comes almost six weeks after FDA authorized extra doses of the Pfizer or Moderna COVID-19 vaccine for people who are severely immunocompromised.
FDA authorizes booster dose of Pfizer COVID-19 vaccine for people 65 and older, high-risk workers